The role of radiolabeled somatostatin analogs in adrenal imaging

https://doi.org/10.1016/0969-8051(96)00065-0Get rights and content

Abstract

We investigated the role of radiolabeled somatostatin analogs (SAs) in adrenal imaging. We evaluated 15 patients (6 men and 9 women, mean age 47 ± 17 years) with imaging-detected adrenal tumors. Patient population was divided into two groups on the basis of the nature of adrenal lesions. Group 1 consisted of patients with benign adrenal lesions (n = 10). Group 2 consisted of patients with malignant adrenal lesions (n = 5). Pathology examinations were obtained in 13 cases: 7 pheochromocytomas, 2 adenomas, 2 cysts, 1 carcinoma, and 1 fibro-histiocytoma. One patient had a proven diagnosis of non-small-cell lung cancer associated with the presence of a right adrenal mass. The last patient had a clinical diagnosis of Werner syndrome associated with the presence of a large left adrenal mass. All patients underwent scintigraphic studies using radiolabeled SAs, of which indium-111 (In-111) pentetreotide was used in 11 cases and technetium-99m (Tc-99m)-labeled peptides (P-587 or P-829) were used in the remaining four cases. No significant labeled SAs uptake was observed in the majority (8 of 10, 80%) of the benign adrenal lesions (Group 1); however, increased uptake was found in two benign pheochromocytomas. Conversely, significant labeled SAs uptake was observed in the majority (4 of 5, 80%) of the malignant adrenal lesions (Group 2); however, the last lesion (carcinoma) did not show abnormal uptake. Results of this study show that the majority of benign adrenal tumors do not concentrate radiolabeled SAs; conversely, the majority of malignant adrenal lesions show significant SAs uptake, suggesting the presence of somatostatin receptors. This finding may allow the use of somatostatin as a treatment agent in malignant adrenal tumors. Thus, the main role of labeled SAs in adrenal imaging consists of lesion characterization rather than tumor detection and localization.

References (21)

  • G.W. Boland et al.

    Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-d-glucose

    Radiology

    (1995)
  • T.H.M. Falke et al.

    Classification of silent adrenal masses: Time to get practical

    J. Nucl. Med.

    (1994)
  • A.J. Fischman et al.

    A ticket to ride: Peptide radiopharmaceuticals

    J. Nucl. Med.

    (1993)
  • I.R. Francis et al.

    Integrated imaging of adrenal disease

    Radiology

    (1992)
  • G.M. Glazer et al.

    Adrenal tissue characterization using MR imaging

    Radiology

    (1986)
  • M.D. Gross et al.

    Scintigraphic evaluation of clinically silent adrenal masses

    J. Nucl. Med.

    (1994)
  • C.A. Hoefnagel

    Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumors

    Eur. J. Nucl. Med.

    (1994)
  • R. Kier et al.

    MR characterization of adrenal masses: Field strength and pulse sequence considerations

    Radiology

    (1989)
  • E.P. Krenning et al.

    Somatostatin receptor scintigraphy with In-111-DTPA-Phe and 1-123-Tyr-octreotide: The Rotterdam experience with more than 1000 patients

    Eur. J. Nucl. Med.

    (1993)
  • S.W.J. Lamberts et al.

    The role of somatostatin and its analogs in the diagnosis and treatment of tumors

    Endocr. Rev.

    (1991)
There are more references available in the full text version of this article.

Cited by (30)

  • PET Imaging of Pheochromocytoma

    2007, PET Clinics
    Citation Excerpt :

    As many as 20% of PCs are extra-adrenal in location59 and tend to be malignant and frequently multicentric. The affinity of these extra-adrenal PCs to MIBG is lower when compared with adrenal PCs, and several authors have demonstrated that imaging with somatostatin analogs such as 111In octreotide is more sensitive in the detection of malignant rather than benign PCs.21,59–62 Further studies analyzing 123I-MIBG–negative metastatic lesions have noted that imaging with somatostatin analogs is complementary to that of 123I-MIBG scanning.63–66

  • Management approaches to adrenal incidentalomas: A view from Ancona, Italy

    2000, Endocrinology and Metabolism Clinics of North America
View all citing articles on Scopus
View full text